Neon Therapeutics racks up $70 mln Series B
Cambridge, Massachusetts-based Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, has closed $70 million in Series B financing. Partner Fund Management led the round with participation from Third Rock Ventures, Access Industries, Fidelity Management & Research Company, Wellington Management Company, Inbio Ventures and Nextech Invest.
5 January 2017•1 min read
